Lung Cancer Screening Saves Lives, but Could Save So Many More
Menée aux Etats-Unis, cette étude examine l'utilisation du dépistage annuel du cancer du poumon puis estime, en fonction du taux d'utilisation (taux actuel puis taux de 100 %), le nombre de décès évités et le nombre d'années de vie gagnées grâce à ce dépistage
Lung cancer has remained the leading cause of cancer death among men in the US since the early 1950s, among women in the US since 1987, and worldwide for several decades. Lung cancer screening with low-dose computed tomography (LDCT) significantly reduced lung cancer mortality in 2 large-scale randomized clinical trials and is currently recommended in the US for an estimated 13 million high-risk adults, offering a tremendous opportunity to reduce mortality from the deadliest cancer. Yet, implementation of lung cancer screening has been challenging, and more than 80% of adults eligible for screening do not get screened. Moreover, recent evidence suggests that current eligibility criteria for screening inadequately identify high-risk populations and exclude approximately 50% of adults diagnosed with lung cancer.
JAMA , éditorial, 2025